<DOC>
	<DOCNO>NCT00299234</DOCNO>
	<brief_summary>This study double-blind , placebo-controlled , parallel group trial atomoxetine ( 1.8 mg/kg ) management chemotherapy-related acquire attentional disorder child survive Acute Lymphocytic Leukemia . Atomoxetine produce favorable impact ADHD symptoms child chemo-related acquire attentional disorder .</brief_summary>
	<brief_title>Atomoxetine Children With Acquired Attentional Disorders Following Completion Chemotherapy ALL</brief_title>
	<detailed_description>The primary objective study ass safety , tolerability efficacy atomoxetine determine change ADHD-RS-IV Total score compare placebo symptomatic treatment patient diagnose Attention-Deficit/Hyperactivity Disorder ( DSM-IV ADHD-NOS criterion ) occur neuropsychological late-effect chemotherapy use treat Acute Lymphocytic Leukemia ( ALL ) . The secondary objective : 1. assess effect daily ( AM ) dose atomoxetine ( 1.8mg/kg ) compare placebo ADHD symptom measure : - ADHD-RS Total score inclusive subtypes inattention , hyperactivity combine subtypes . - Clinical Global Impression-ADHD 2. evaluate safety tolerability atomoxetine compare placebo base treatment-emergent adverse event ( AEs ) , laboratory test , vital sign , physical examination , ECGs .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Ages 618 year Must successfully complete treatment ALL currently 1year `` disease free '' judge investigator . Must meet DSMIV criterion `` ADHDNOS . ( Attachment A ) The attention deficit symptom precipitate chemotherapyrelated neurological injury . Therefore , DSMIV category ADHDNOS . Must Investigatorcompleted ADHDRS total and/or subscale score â‰¥1.5 standard deviation age/gender norm . Laboratory result , include chemistry , hematology , urinalysis demonstrate clinically significant abnormality . ECG demonstrate clinically significant abnormality Educational level degree understand patient parent permit suitable communication investigator study coordinator . Subjects parent judge reliable keep appointment . Must able swallow tablet . Must demonstrate compliance chemotherapy program . Must weigh &gt; 20 kg . Have relapse reoccurring symptoms/signs ALL . Have substantial exposure radiation therapy ( &gt; 2000 : cGy ) since high dose radiation treatment associate neurocognitive deficit `` treatment resistant '' pharmacologically . Past exposure atomoxetine . ADHD symptoms treatment prior diagnosis ALL Documented bipolar disorder , psychosis , affective disorder . Female subject pregnant breastfeeding . Suicide risk . Seizure disorder ( except history febrile seizure ) . Histories multiple drug allergy . Histories alcohol substance abuse . Prior current medical condition , opinion investigator , could exacerbate atomoxetine . Sympathomimetic overactivity catecholamine secrete tumor . Use MAOI medication . Have take psychostimulants one week prior randomization . Current past history hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
</DOC>